Back | Next |
home / stock / avxl / avxl message board
Subject | By | Source | When |
---|---|---|---|
Boi, I agree that there has been an | WilliamMunny | investorshub | 07/23/2024 2:02:45 PM |
I doubt that's the explanation. This appears to | boi568 | investorshub | 07/23/2024 1:57:49 PM |
Good volume too. I wonder if EF Hutton | ignatiusrielly35 | investorshub | 07/23/2024 1:51:58 PM |
Anavex Life Sciences Corp. ($AVXL) | nidan7500 | investorshub | 07/23/2024 1:50:59 PM |
Rapporteurs are assigned by the CHMP within 7 | frrol | investorshub | 07/23/2024 1:50:03 PM |
$AVXL up $0.32 that is a good start | georgejjl | investorshub | 07/23/2024 1:49:42 PM |
New brokerage firm. New audience. The | WilliamMunny | investorshub | 07/23/2024 1:46:43 PM |
Coming presentations by Anavex | georgejjl | investorshub | 07/23/2024 1:37:34 PM |
AAIC no show this year...typical Misleading | kund | investorshub | 07/23/2024 1:20:57 PM |
MAA would typically be submitted 7 months after | Hoskuld | investorshub | 07/23/2024 11:58:16 AM |
other than for an end point the FDA | Hoskuld | investorshub | 07/23/2024 11:56:45 AM |
pete [quote: These unsolicited studies crediting Anavex with | nidan7500 | investorshub | 07/23/2024 11:36:38 AM |
We already have the results for $AVXL, they | Hosai | investorshub | 07/23/2024 10:59:50 AM |
The SEC definition is at odds with clinical | Investor2014 | investorshub | 07/23/2024 9:05:51 AM |
My opinion on that is filing an MAA | Steady_T | investorshub | 07/23/2024 7:18:08 AM |
For SAVA that has a drug which is | crescentmotor | investorshub | 07/23/2024 7:14:15 AM |
Jupiter Asset Management Ltd. lifted its stake in | georgejjl | investorshub | 07/23/2024 5:32:55 AM |
SAVA up 28% today on a rosy outlook | Talon38 | investorshub | 07/23/2024 5:10:12 AM |
Missling perhaps? | Investor2014 | investorshub | 07/23/2024 4:52:18 AM |
So when do you think we would hear | Jonjones325 | investorshub | 07/23/2024 4:12:02 AM |
News, Short Squeeze, Breakout and More Instantly...
Anavex Life Sciences Corp. Company Name:
AVXL Stock Symbol:
NASDAQ Market:
Anavex Life Sciences Corp. Website:
Oral, once daily blarcamesine significantly slowed clinical decline for early Alzheimer's disease patients with good comparative safety profile and no associated neuroimaging adverse events Clinical benefit of blarcamesine consistently observed for both 30 mg and 50 mg treatment groups ...
2024-07-18 02:34:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
NEW YORK, June 20, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative, neurodevelopmental and neuropsyc...